Standout Papers

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma 2020 2026 2022 2024229
  1. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma (2020)
    Matthias Pinter, Rakesh K. Jain et al. JAMA Oncology
  2. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
    Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 7 from Science/Nature 82 standout
Sub-graph 1 of 21

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
2025 Standout
1 intermediate paper

Works of Matthias Pinter being referenced

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
2024 Standout
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
2013

Author Peers

Author Last Decade Papers Cites
Matthias Pinter 2815 1987 1066 150 4.5k
Wolfgang Sieghart 2527 1776 977 86 4.6k
Si Hyun Bae 3743 2553 784 237 5.4k
Kazuhiro Nouso 2454 1881 1081 217 4.9k
Su Jong Yu 3115 2762 1151 270 5.9k
Li Xu 2449 1143 1248 193 4.9k
Won Young Tak 3261 2223 879 195 5.7k
Ju Hyun Shim 4001 2882 960 209 5.4k
Jong Eun Yeon 1924 1745 538 185 3.7k
Jian‐Hong Zhong 2430 1447 952 174 4.1k
Minshan Chen 2928 1334 1276 188 4.8k

All Works

Loading papers...

Rankless by CCL
2026